Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Network Group BayHelix Links Life Sciences Leaders To Blaze New Trail In China – An Interview With PharmAsia News (Part 2 of 2)

This article was originally published in PharmAsia News

Executive Summary

BayHelix is a non-profit, invitation-only organization for ethnic Chinese leaders in the global life sciences arena. Created in the San Francisco Bay Area in 2001, BayHelix has since become a bridge linking 300-plus Chinese business, law and science professionals in the health care industry across the U.S., Canada and Greater China. Recently the chairman of BayHelix, James Zhu, managing partner of Perkins Coie's Beijing Office, and the group's two co-founders, Jonathan Wang, OrbiMed's managing director in Asia, and Steve Yang, vice president, Head of Asia R&D at Pfizer, sat down with PharmAsia News' Shanghai Bureau to talk about the founding and the future of BayHelix as well as the challenges and opportunities in China's life sciences sector.

You may also be interested in...



Looking At The Universe Of Possibilities In China: An Interview With Eli Lilly China R&D Head Tony Zhang

It's about being a "sower and a grower" not a "seeker and a picker," Zhang said of Lilly's FIPNET philosophy.

Looking At The Universe Of Possibilities In China: An Interview With Eli Lilly China R&D Head Tony Zhang

It's about being a "sower and a grower" not a "seeker and a picker," Zhang said of Lilly's FIPNET philosophy.

Eli Lilly's China R&D Head Tony Zhang On Looking At The Universe Of Possibilities In China: An Interview With PharmAsia News

Eli Lilly was the first to coin the term FIPNET, which brings the focus of becoming a fully integrated pharmaceutical network on partnerships rather than doing it all as a fully integrated pharmaceutical company, or FIPCO. Eli Lilly's Head of China R&D Tony Zhang sat down with PharmAsia News along the sidelines of the recent Shanghai R&D Summit to discuss Lilly's approach to R&D in China. Much of doing R&D in China is about building up a local ecosystem for innovation and, according to Zhang, it is about being a "sower and a grower," rather than just a "seeker and a picker."

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

SC070861

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel